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Title 
Pragmatic randomised controlled trial of periarticular infiltration versus femoral nerve 
blockade for early pain relief following total knee replacement surgery 
 
Abstract 
Aims 
To determine the comparative clinical effectiveness of periarticular infiltration versus 
femoral nerve block for managing early postoperative pain after total knee replacement. 
Methods 
A pragmatic, single centre, two arm parallel group, participant blinded randomised 
controlled trial was completed. Patients due for total knee replacement surgery at Hospital 
[BLINDED] were eligible. Exclusions included contraindications to intervention medications 
and abnormal lower leg neurology. Participants received either femoral nerve block with 
75mg of 0.25% levobupivacaine hydrochloride around the nerve or periarticular knee 
infiltration with 150mg of 0.25% levobupivacaine hydrochloride, 10mg morphine sulphate, 
30mg ketorolac trometamol and 0.25mg of adrenaline all diluted with 0.9% saline to make 
a volume of 150ml. 
Results 
264 participants were recruited and data was available on 230 participants (88%) for 
primary analysis.  Intention to treat analysis of the primary outcome for pain (visual 
analogue scale) on day one prior to physiotherapy was similar between groups; mean 
difference -0.7, P=0.834 (95% CI -5.9 to 4.5). The periarticular group used less morphine in 
the first 24 hours compared to the femoral nerve block group (74% 95% CI 55 to 99). The 
femoral nerve block group reported 39 adverse events (27 serious) in 31 participants and 
the periarticular group 51 adverse events (38 serious) in 42 participants up to 6 weeks 
postoperatively. None of the reported adverse events were directly attributed to either of 
the interventions under investigation. 
Conclusion 
Periarticular infiltration is a viable and safe alternative to femoral nerve block for early 
postoperative pain relief following total knee replacement surgery. 
 
Trial registration 
The study has been registered with the current controlled trials database under reference 
number [Blinded]. 
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Introduction 
Around 93,000 total knee replacements (TKR) were performed within the National Health 
Service (NHS) in 2014; a 200% increase since 2004.
1
 In the early postoperative phase after 
TKR surgery, patients can experience substantial pain.
2
 Evidence suggests that femoral 
nerve block, as a single perioperative infiltration of local anaesthetic improves 
postoperative pain control and reduces the need for systemic analgesics such as opiates.
2
 
Femoral nerve block is a standard perioperative analgesic regime administered for early 
relief of pain following surgery.
3
 However, femoral nerve block does not provide analgesic 
effects to the posterior aspect of the knee joint, which is supplied by the sciatic nerve, and 
so pain relief is often incomplete. Femoral nerve block is also associated with rare but 
serious complications including damage to the adjacent major blood vessels as well as 
damage to the nerve itself.
2
 In all cases, femoral nerve block temporarily impairs 
quadriceps muscle function which is important for knee extension, and as a result can lead 
to falls after surgery.
2,4
 Alternative analgesic regimes include an adductor canal block, but 
this also does not provide analgesic effects to the back of the knee.
5
 
 
A popular alternative approach to femoral nerve block is intraoperative periarticular 
infiltration of analgesic agents including: local anaesthetics, opiates and non-steroids anti-
inflammatory drugs. Periarticular infiltration has the advantage of delivering analgesics 
directly to the sources of pain, thereby reducing the risk of systemic side effects.
6
 
Periarticular infiltration can be administered by the operating surgeon without any 
specialist equipment compared to a femoral nerve block which requires ultrasound or a 
nerve stimulator or both to be safely administered. In contrast to femoral nerve blockade, 
periarticular infiltration does not inhibit quadriceps function and can provide analgesia 
effects to the whole of the knee joint.
2
 However, there is limited evidence to support the 
routine use of periarticular infiltration to control early postoperative pain.
2,7,8
 
 
We report a randomised clinical trial (RCT) comparing periarticular infiltration versus 
femoral nerve block for patients undergoing TKR surgery to establish the most effective 
intervention for early (within 24 hours) postoperative pain relief.           
 
Patients and Methods 
Study population 
This was a single centre, two arm parallel group RCT undertaken at the National Health 
Service, Hospital [Blinded]. Participants were recruited between December 2013 and 
October 2015. All patients undergoing an elective primary unilateral TKR were potentially 
eligible.  Our exclusion criteria were: 
i. Concomitant medical or psychiatric problems which would prevent completion of 
treatment or follow-up. 
ii. Pre-operative history of neurological abnormality in the ipsilateral leg e.g. history of 
stoke, neurogenic pain or previous nerve pain. 
iii. Specific contraindication to the analgesic agents used. 
iv. Participation in a clinical trial of an investigational medicinal product in the last 90 days. 
v. Previous entry in the present trial. 
vi. Participant unable to adhere to trial procedures.  
 
Randomisation 
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Participants were allocated to trial treatments through a remote, telephone 1:1 
randomisation service using a computer generated randomisation schedule created using 
randomised blocks and stratified by anaesthetic type (general or spinal). Block sizes were 
randomly chosen to ensure concealment. Randomisation was undertaken by an 
independent member of the theatre operating staff on the day of surgery after the 
participant had received a spinal and sedation or general anaesthetic. 
 
Interventions 
All participants were invited to attend the hospitals routine pre-operative TKR education 
class. Unless contraindicated, participants were given premedication gabapentin. 
Participants received spinal anaesthetic and sedation or a general anaesthetic. After 
randomisation participants were allocated to either:  
i. Femoral nerve block. The technique involved identification of the femoral nerve 
below the inguinal ligament using nerve stimulation and/or ultrasound, as per the 
treating anaesthetist’s normal clinical practice and infiltration of 75mg of 0.25% 
levobupivacaine hydrochloride around the nerve.  
Or 
ii. Periarticular infiltration The technique involved: 150mg of 0.25% levobupivacaine 
hydrochloride, 10mg morphine sulphate, 30mg ketorolac trometamol and 0.25mg 
of adrenaline all diluted with 0.9% saline to make a volume of 150ml. Infiltration of 
the periarticular mixture was into the skin and soft tissues of the knee by the 
operating surgeon. The zones of infiltration included: the medial, lateral, 
suprapatellar and posterior soft tissues structures. Surgeons were advised to 
infiltrate roughly equal quantities to all four zones. 
The fidelity with which both interventions were delivered was reviewed by an independent 
clinician who observed and audited practice against the intervention protocols described. 
The results were relayed to those delivering the interventions in order to maintain ongoing 
protocol compliance. 
The remainder of the operation was performed according to the surgeons’ routine clinical 
practice for performing a TKR.  All participants followed the same standardised TKR 
pathway after surgery unless they had specific contraindications; all patients receiving 
postoperative regular paracetamol, ibuprofen and gabapentin and morphine sulphate 
sustained release. Oramorph was administered as required and titrated according to 
participants’ pain. Standard hospital prophylaxis for venous thromboembolism (VTE) was 
administered to all participants unless contraindicated. VTE prophylaxis included: 
intermittent positive pressure calf compression until mobile and subcutaneous low 
molecular heparin for 14 days after surgery.     
 
Outcomes 
Baseline patient characteristics and preoperative functional status were collected after 
consent was given. The primary outcome measure was a 100mm visual analogue score 
(VAS) of pain reported by the patient on the first day after surgery and prior to 
physiotherapy commencing. The 100mm VAS with 0 being no pain and 100mm being the 
worst pain is a validated patient reported outcome measure for pain following TKR 
surgery.
8
 The primary end point was chosen after patient feedback indicating that 
adequate pain relief on the first day after surgery, in preparation for physiotherapy, was of 
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principal importance to the study population; this is consistent with  other smaller  RCTs 
which have also used this time point.
9-11
 
Secondary outcome measures were: 
i. Pain after physiotherapy on day one postoperatively and pain before and after 
physiotherapy on day two postoperatively, using the same VAS as the primary 
outcome 
ii. Functional assessment by a physiotherapist using straight leg raise and knee range 
of movement (ROM) and ability to transfer from bed to chair and time taken to rise 
from a chair, walk three meters, turn around, walk back to the chair, and sit down 
(timed up and go) 
iii. Total opiate, paracetamol, ibuprofen and gabapentin analgesia used up to 24 and 
48 hours after surgery. All opiates were converted to a morphine equivalent dose 
using a multiplication conversion factor of 0.1 for codeine and tramadol, as 
outlined in the British National Formulary (BNF).
12
  
iv. Oxford Knee Score (OKS) at six weeks after surgery. OKS is a validated self-
administered osteoarthritis outcome measure.
13
 
v. EuroQol (EQ-5D-5l) at six weeks after surgery. The EQ-5D is a validated measure of 
health-related quality of life, consisting of a five dimension health status 
classification system and a separate visual analogue scale.
14,15
 The EQ-5D-5L was 
used and the utility values were calculated using the 3L crosswalk value sets.
16
 
vi. Douleur Neuropathic Pain (DN2/Seven Item DN4) Score at six weeks after surgery. 
DN2 is a tool for assessing neuropathic pain consisting of two questions.
17,18
  
vii. Adverse events (AE) up to six weeks after surgery. An AE was defined as any 
untoward medical occurrence in a participant, which does not necessarily have a 
causal relationship with the treatment. AEs were further classified into serious 
adverse events (SAEs) if they fulfilled any of the following criteria: immediately life-
threatening, required hospitalisation or prolongation of existing hospitalization, 
resulted in persistent or significant disability or incapacity, resulted in a congenital 
abnormality or a birth defect, regarded by the study team as an important medical 
condition. 
Although not reported in this study participants were followed up to 12 months with OKS, 
EQ-5D-5L, DN2 and AEs.
19
 The additional outcome data is being used to help inform the 
design of a future trial examining chronic pain after TKR surgery. 
 
Blinding 
Patients were blind to the intervention to which they were allocated. Allocation 
concealment was maintained by ensuring randomisation was performed after spinal and 
sedation or general anaesthetic and then administered within a sterile zone with drapes to 
physically prevent patients seeing which intervention they received. In addition to ensure 
postoperative concealment all participants had a standard dressing applied to the area 
where a femoral nerve block is usually performed. Due to the nature of the study it was 
not possible to blind the surgeon and anaesthetist delivering the interventions to the 
treatment options. Outcome data was collected by an independent clinical physiotherapist 
who was blinded to the treatment allocation. 
 
The trial protocol was prepared in accordance with the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) guidelines and published a priori.
19,20
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Statutory research & ethical committee (REC) approval was obtained 23
rd
 September 2013 
[Blinded]. The trial was conducted in accordance with the Medicines for Human use 
(Clinical Trials) Regulations 2004, the International Conference on Harmonisation Good 
Clinical Practice (ICH GCP) and reported in line with the Consolidated Standards of 
Reporting Trials (CONSORT) statement.
21
 
 
Patient involvement 
Patients were consulted during their routine clinical appointments to determine if the 
research question was important to them and participants in a successful pilot trial were 
asked to provide feedback on the trial processes.
20
 A small number of pilot trial participants 
helped to develop the full trial proposal including the choice of primary outcome measure. A 
patient member was part of the trial steering group and had an active role in overseeing the 
running of the trial including mechanisms for disseminating the results. 
 
Sample size and analysis plan 
The available literature, suggested a between group difference in the VAS of 12 mm (95% 
CI 9mm-15mm) to be the minimum clinically important difference (MCID).
22
 Based upon 
pilot data, the observed standard deviation for VAS was 30mm.
23
 Therefore to test the null 
hypothesis of equality of the treatment group means, assuming approximate normality for 
the VAS, 264 patients (132 in each arm) were required for 90% power and 5% significance. 
Initial analysis investigated differences in the primary outcome score on an intention to 
treat basis using an independent samples t-test. The t-test was augmented with a linear 
regression that adjusted for age, gender and anaesthetic type. Tests were two-sided and 
considered to provide evidence for a significant difference if p-values were less than 5%. 
Estimates of treatment effects were presented with 95% confidence intervals. For 
continuous approximately normally distributed secondary outcome measures (e.g. OKS, 
EQ-5D), data was analysed in a similar manner to the primary outcome. In hospital 
medication variables were log transformed prior to testing to better approximate the 
normal distribution. Count data, such as adverse events, were compared between groups 
using chi-squared tests. 
Some data were not available due to voluntary withdrawal of patients, lack of completion 
of individual data items or general loss to follow-up. Where possible the reasons for 
missing data were determined and reported. All analysis presented are based on complete 
cases. 
Analysis was implemented using the software package R.
24
 
 
Results 
Participants 
From March 2014 to November 2015, 264 patients were recruited, of these 262 were 
randomised. Two patients were not randomised due to a data entry error. Figure 1 shows 
the flow of participants from screening, application of eligibility criteria through to final 
follow up. Baseline characteristics including age, sex, knee function (OKS) and general 
quality of life (EQ-5D-5L) for both groups of patients was broadly similar, see Table 1.  
A total of 59 anaesthetists performed the femoral nerve blocks (median three 
interventions per anaesthetist, interquartile range one to seven; three operation notes did 
not list the anaesthetist) and 33 surgeons performed the periarticular infiltrations (median 
four interventions per surgeon, interquartile range two to 11).     
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Primary analysis – see Table 2 
On an intention to treat primary analysis the mean treatment difference between groups 
was not statistically significant; -0.9 (P=0.770, 95% CI -5.3 to 7.2). Using multiple linear 
regression to adjust for age, gender and anaesthetic type the mean treatment difference 
between groups was not statistically significant, -0.7 (P=0.834, 95% CI -5.9 to 4.5).  
 
Secondary analysis – see Table 2 and Table 3 
On day one after physiotherapy mean pain scores increased in both groups, (femoral nerve 
block group mean=49, periarticular group mean=52, however there was no statistically 
significant treatment difference between groups; -2.7 (P=0.371, 95% CI -8.6 to 3.2). Mean 
differences in pain scores on day two both before and after physiotherapy, were also not 
statistically different between groups, 2.7 (P=0.435, 95% CI -4.2 to 9.7) and 1.8 (P=0.591, 
95% CI -4.8 to 8.3) respectively. Figure 2 shows the pain scores on day one and two as box 
plots.  
 
The proportion of patients able to transfer from bed to chair independently on day one 
(treatment difference -7.5%; P=0.069, 95% CI -20.7 to 5.7) and the mean time in seconds 
to get up and go on day two (treatment difference 16.4 seconds; P=0.051, 95% CI -0.1 to 
33.0), were both marginally in favour of periarticular infiltration and had borderline 
statistical significance. The mean knee flexion angle (degrees) at day two was better in the 
periarticular group, however the difference between treatment arms was small at -5.4 
degrees (P=0.005, 95% CI -9.1 to -1.6). Amongst the remaining day one and two functional 
outcomes there was no significant difference between groups: straight leg raise ability (day 
one P = 0.192 and day two P=0.219), ability to transfer independently (day one P=0.069 
and day two P=0.254) and timed up and go (day one P=0.161 and day two P=0.349).   
 
Analgesic use (total dose in mg) was log-transformed prior to analysis. There was no 
significant statistical difference up to 24 and 48 hours after surgery in use of paracetamol 
(P=0.338 and 0.817 respectively), ibuprofen (P=0.285 and 0.309 respectively) or 
gabapentin (P=0.835 and 0.671 respectively) which were given to all patients as a matter 
of routine. However, the requirement for morphine which was administered according to 
participants’ pain was less up to 24 hours in those receiving periarticular infiltration (74% 
of the total dose given to the femoral nerve block group, P=0.042, 95% CI 55 to 99). At 48 
hours there was no statistically significant difference in morphine equivalent dose 
(P=0.203), see Table 3.  
 
At six weeks there was no statistically significant treatment differences in mean EQ-5D (-
0.01, P=0.670, 95% CI -0.06 to 0.04), OKS (-0.4, P=0.673, 95% CI -2.4 to 1.5) or DN2 scores 
(0.4, P=0.118, 95% CI -0.04 to 0.77). 
 
There were two deaths during the trial period. One patient died due to a myocardial 
infarction, and had been allocated to and received periarticular infiltration, see Table 4. 
One patient died due to sepsis, and had been allocated to and received a femoral nerve 
block. There were 51 adverse events (38 serious) amongst 42 participants in the group 
allocated to periarticular infiltration and 39 (27 serious) amongst 31 participants in those 
allocated to femoral nerve block, see Table 4. The most frequent adverse events were: 
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superficial wound infection (15 reports), acute kidney injury (9 reports) and chest infection 
(8 reports). None of the reported adverse events were directly attributed to either of the 
interventions under investigation. 
 
Following the primary analysis, we did a post-hoc per protocol analysis for equivalence of 
outcome. The mean treatment difference was not statistically significant 0.04 (P=0.990, 
95%CI -6.2 to 6.3). 
 
Discussion 
This trial shows that pain scores the day after TKR surgery are the same between 
participants who have had a femoral nerve block and those who have had periarticular 
infiltration. This study was not designed to show equivalence in outcomes, however, the 
95% confidence interval limits for the treatment difference, in the per protocol analysis, 
were only just over half of the pre-specified clinically important difference. We can, 
therefore be confident that we have excluded a clinically important difference in pain 
scores on day one between the two interventions.  
 
Although pain scores were similar between groups, the use of morphine pain medication 
up to 24 hours after surgery was less in those participants allocated to periarticular 
infiltration. Although morphine is an effective supplementary analgesic for postoperative 
pain, dose dependent systemic side effects, including nausea, vomiting, respiratory 
depression, pruritus, reduced gut mobility, and urinary retention mean that lower doses 
are preferable.
25
  
 
Two other early functional secondary outcomes had borderline significant differences 
between groups (the ability to transfer independently on day one and knee flexion on day 
two) and both were in favour of periarticular infiltration. Although caution is needed in 
interpreting the relevance of the secondary observations these and the primary outcome 
findings do support the notion that periarticular infiltration is a good alternative to femoral 
nerve block. Both interventions are designed to provide early analgesic effects and by six 
weeks we found no evidence of a difference in patient reported outcome measures 
between the two groups. 
 
None of the reported adverse events were directly attributed to either of the interventions 
under investigation. Furthermore, the frequency of adverse events was broadly similar in 
both treatment groups, and were comparable to those reported in the literature, 
suggesting that periarticular infiltration does not pose any additional risk to patients.
26-28
  
 
Periarticular infiltration has previously been compared to femoral nerve block for early pain 
relief following TKR surgery in three small RCTs (collectively 181 participants).
9-11
 However, 
meta-analyses (Marques et al 2014 
8
, Chan et al 2014 
2
 - a Cochrane review – and Albrecht 
et al 2016
29
) of these RCTs have been unable to draw firm conclusions about the 
comparative effectiveness of periarticular infiltration versus femoral nerve block largely 
because of a lack of statistical power and moderate quality (GRADE
30
) evidence. Our results 
now show that periarticular infiltration offers comparable early pain relief and safety profile. 
Patients and clinicians should therefore consider other factors including the availability of 
specialist equipment (e.g. nerve stimulator or ultrasound for administering the femoral 
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nerve block) and any specific contraindications when making a preference for either 
intervention.  
  
Strengths and limitations 
The main strengths of this trial are patient blinded outcome assessment and its pragmatic 
design. The trial followed a published protocol and included an intention to treat primary 
analysis. This means that the findings should be applicable to routine clinical practice.  
The main weakness is that the study involved only one centre in the NHS. Although, the 
trial included many different surgeons and anaesthetists, the study should be replicated in 
other healthcare settings. The trial has tested only one regime of periarticular infiltration, 
but others exist including different types of local anaesthetic and dosing. However, the 
regime we chose and tested was representative of our region and many hospitals 
throughout the United Kingdom. A data entry error resulted in the final sample for primary 
analysis being two less than anticipated. However, the evaluated treatment difference of -
0.9 is less than the minimum clinically important difference of 1.2, and smaller than the 
anticipated standard deviation, we are therefore confident that the study is not 
underpowered and there is no clinical difference between the two treatment arms.” 
 
In conclusion there is no clinically meaningful difference in patient perception of pain the 
day after TKR surgery between those that have a femoral nerve block and those having 
periarticular infiltration. Periarticular infiltration which can be administered without the 
need for specialist additional equipment and reduces postoperative morphine 
requirements should be considered as a viable and safe alternative to femoral nerve block 
for early pain relief following TKR surgery.  
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Tables 
 
Table 1: Baseline characteristics of patients 
Patient characteristic Femoral Nerve Block (n=131) Periarticular (n=131) 
Sex Male, n (%) 51 (38.9) 54 (41.2) 
Age, mean (sd) 68.2 (10.0) 68.7 (9.6) 
Weight, mean (sd) 82.0 (17.2) 83.2 (17.6) 
Smoker Yes, n (%) 13 (10.2) 10 (7.8) 
OKS, mean (sd) 23.0 (6.8) 23.5 (7.9) 
EQ-5D-5L, mean (sd) 0.5 (0.2) 0.5 (0.2) 
Received spinal anaesthetic (remainder 
received general anaesthetic), n (%) 
78 (48) 86 (52) 
 
Table 2: Main outcomes (excluding analgesia use and adverse events)  
Outcome 
Femoral 
nerve 
block 
Periarticular 
No. of valid 
responses P 
Treatment 
difference 
(95% CI) FNB PI 
Pain score day 1 pre 
physiotherapy 
44.1 
(23.0) 
43.2 (24.9) 113 117 0.770 -0.9 (-5.3 to 
7.2) 
Pain score day 1 pre physio; 
per protocol 
43.7 
(23.5) 
43.7 (24.6) 112 116 0.990 0.04 (-6.2 to 
6.3) 
Pain score day 1 after 
physiotherapy 
49.0 
(22.4) 
51.7 (22.0) 108 111 0.371 -2.7 (-8.6 to 
3.2) 
Pain score day 2 before 
physiotherapy 
40.8 
(26.4) 
38.1 (24.3) 107 102 0.435 2.7 (-4.2 to 
9.7) 
Pain score day 2 after 
physiotherapy 
43.3 
(24.1) 
41.5 (22.6) 100 98 0.591 1.8 (-4.8 to 
8.3) 
No. able to straight leg raise 
day 1 (%) 
50 
(42.4) 
61 (51.7) 118 118 0.192 -9.3 (-22.8 to 
4.2)  
No. able to straight leg raise 
day 2 (%) 
44 
(41.1) 
53 (50.5) 100 105 0.219 -9.4 (-0.23.7 to 
4.9) 
Knee 
ROM day 
1 in 
degrees 
Extension angle 
-5.4 
(7.4) 
-3.5 (12.9 118 117 0.174 -1.7 (-4.6 to 
0.8) 
Flexion angle 
67.4 
(18.2) 
72.8 (40.9) 118 117 0.197 -5.4 (-13.5 to 
2.8) 
Knee 
ROM day 
2 in 
degrees 
Extension angle 
-4.6 
(6.4) 
-4.8 (5.6) 111 103 0.848 0.1 (-1.4 to 
1.8) 
Flexion angle 
73.6 
(14.2) 
79.0 (13.6) 110 103 0.005* -5.4 (-9.1 to -
1.6) 
Ability to 
transfer 
day 1 
No. 
independent 
(%) 
44 
(36.1) 
51 (43.6) 
122 117 0.069 
-7.5 (-20.7 to 
5.7) 
No. assistance 
of 1 (%) 
42 
(34.4) 
47 (40.2) -5.8 (-18.8 to 
7.3) 
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No. assistance 
of 2 (%) 
15 
(12.3) 
5 (4.3) 8.0 (0.3 to 
15.7) 
No. unable (%) 
21 
(17.2) 
14 (12.0) 5.2 (-4.5 to 
15.0) 
Ability to 
transfer 
day 2 
No. 
independent 
(%) 
69 
(62.7) 
76 (72.4) 
110 105 0.254† 
-9.7 (-23.0 to 
3.7) 
No. assistance 
of 1 (%) 
30 
(27.3) 
19 (18.1) 9.2 (-2.9 to 
21.2) 
No. assistance 
of 2 (%) 
6 (5.5) 6 (5.7) -0.2 (-6.7 to 
6.1) 
No. unable (%) 
5 (4.5) 4 (3.8) 1.6 (-5.3 to 
6.8) 
Timed 
up and 
go day 1 
Time of those 
able in seconds 
99.3 
(51.8) 
92.8 (41.8) 61 70 0.436 6.5 (-10.0 to 
22.9) 
No. unable (%) 
53 
(46.5) 
40 (36.4) 114 110 0.161 10.1 (-3.6 to 
23.9) 
Timed 
up and 
go day 2 
Time of those 
able in seconds 
89.8 
(65.8) 
73.3 (41.3) 85 90 0.051 16.4 (-0.1 to 
33.0) 
No. unable (%) 
20 
(19.0) 
14 (13.3) 105 105 0.349 -13.1 (-5.2 to 
16.6) 
EQ-5D-5L at 6 weeks 0.8 (0.2) 0.8 (0.2) 122 123 0.670 -0.01 (-0.06 to 
0.04) 
OKS at 6 weeks 31.0 
(7.2) 
31.4 (8.2) 120 125 0.673 -0.4 (-2.4 to 
1.5) 
DNS-2 at 6 weeks 2.0 (1.6) 1.7 (1.4) 102 108 0.118 0.4 (-0.04 to 
0.77) 
For continuous outcomes, means (standard deviations) are reported and were compared using t-tests. For 
count outcomes, number (percent of valid) are reported and were compared using χ2 tests. Analyses are 
intention to treat unless stated 
†to conduct χ2 test, due to small cell counts “assistance of 2” and “unable” responses have been combined. 
* <0.05 therefore reached significance 
 
 
Table 3: Analgesic use up to 24 and 48 hours (log transformed treatment difference) 
Analgesia type and timing 
Femoral Nerve 
Block 
(n=125) 
Periarticular 
(n=120) 
P 
(transformed t-
test) 
Treatment 
difference, % of 
FNB 
(95% CI) 
Paracetamol in 
mg, mean (sd) 
Up to 
24hrs  
3524 (689.4) 3533 (620.8) 0.338 82 (50 to 122) 
24 to 
48hrs 
3720 (929.8) 3791 (818.9) 0.817 94 (55 to 149) 
Ibuprofen in mg, 
mean (sd) 
Up to 
24hrs  
332 (492.7) 265 (436.3) 0.285 67 (30 to 103) 
24 to 
48hrs 
340.6 (531.8) 301.7 (520.5) 0.309 67 (55 to 103) 
Morphine 
equivalent dose 
in mg, mean (sd) 
Up to 
24hrs 
62.7 (39.7) 54.8 (39.8) 0.042* 74 (55 to 99) 
24 to 
48hrs 
40.0 (44.4) 32.5 (28.1) 0.203 82 (55 to 111) 
Gabapentin in 
mg, mean (sd) 
Up to 
24hrs 
492 (354.3) 522 (397.3) 0.835 106 (61 to 182) 
24 to 522.2 (384.7) 580.0 (419.2) 0.671 110 (61 to 201) 
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48hrs  
  
Table 4: Reported adverse events within six weeks of surgery 
Adverse event within six weeks 
Femoral 
nerve 
block 
Periarticular 
Odds ratio of 
AE (95% CI)* 
P 
Death 1 1 1 (0.0 to 79.0) 1 
Cement syndrome (perioperative hypotension) 0 1 - - 
Deep wound infection undergoing revision 0 1 - - 
Superficial wound infection  6 9 0.7 (0.2 to 2.1) 0.596 
Leaking wound no infection 0 1 - - 
Knee instability undergoing revision 0 1 - - 
Wound haematoma 0 1 - - 
Reduced early ROM (physio only) 1 1 1 (0.0 to 79.0) 1 
Reduced early ROM (requiring manipulation) 2 2 1 (0.1 to 14.0) 1 
Leg paraesthesia  1 1 1 (0.0 to 79.0) 1 
Foot drop 0 1 - - 
Morphine overdose 1 3 
0.3 (0.006 to 
4.2) 
0.622 
Acute kidney injury 3 6 0.5 (0.1 to 2.4) 0.500 
Chest Infection  6 2 3.1 (0.5 to 31.8) 0.281 
Leg swelling (no deep vein thrombosis) 2 2 1 (0.1 to 14.0) 1 
Pulmonary embolism 1 0 - - 
Atrial fibrillation 1 0 - - 
Symptomatic anaemia requiring blood 
transfusion 
1 3 0.3 (0.0 to 4.2) 0.622 
Bleeding gastric ulcer 1 1 - - 
Vomiting 1 0 - - 
Gastroenteritis 0 1 - - 
Urinary tract infection 1 0 - - 
Urinary retention 1 2 0.5 (0.0 to 9.7) 1 
Small bowel obstruction 0 1 - - 
Exacerbation of asthma  1 0 - - 
Leg rash 2 2 1 (0.1 to 14.0) 1 
Shingles 1 0 - - 
Leg skin tear 1 0 - - 
Pressure sore 1 0 - - 
Dehydration 1 0 - - 
Admission to manage pain  1 1 1 (0.0 to 79.0) 1 
Admission to remove skin clips 0 1 - - 
Admission no cause found 0 1 - - 
General malaise (no cause found) 1 3 0.3 (0.0 to 4.2) 0.622 
Back pain 1 0 - - 
Total 39 51 0.7 (0.4 to 1.1) 0.152 
Classified as SAE 27 38 0.6 (0.3 to 1.2) 0.152 
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* if only one AE then odds ratio not calculated 
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Figure 1: Overall flow of patients within the trial  
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Figure 2: Box plots of pain scores on day 1 and 2  
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CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 1 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 2 
2b Specific objectives or hypotheses 2 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 2 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants 2 
4b Settings and locations where the data were collected 2 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
3 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
4 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 5 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 5 
8b Type of randomisation; details of any restriction (such as blocking and block size) 2 and 3 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
2 and 3 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
2 and 3 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 4 
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assessing outcomes) and how 
11b If relevant, description of the similarity of interventions N/A 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 5 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 5 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
5 and figure 1 
13b For each group, losses and exclusions after randomisation, together with reasons 5 and 14 – 
figure 1 
Recruitment 14a Dates defining the periods of recruitment and follow-up 5 
14b Why the trial ended or was stopped 5 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 5 and 8 – 
table 1 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
6 and 9 – 
table 2 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
6, 7, 9, 10, 11 
– table 2, 3 
and 4 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 6, 7, 9, 10,11 
– table 2, 3 
and 4 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
6, 7 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 6, 7, 10 and 
11  - table 4 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 7 and 8 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 8 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 7 and 8 
Other information  
Registration 23 Registration number and name of trial registry 1 
Protocol 24 Where the full trial protocol can be accessed, if available 4, 5 and 12 
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Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 8 - blinded 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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The TIDieR (Template for Intervention Description and Replication) Checklist*: 
          Information to include when describing an intervention and the location of the information 
Item 
number 
Item  Where located ** 
 Primary paper 
(page or appendix 
number) 
Other † (details) 
 
BRIEF NAME 
  
1. Provide the name or a phrase that describes the intervention. 1, 2 and 3  
 WHY   
2. Describe any rationale, theory, or goal of the elements essential to the intervention. 3  
 WHAT   
3. Materials: Describe any physical or informational materials used in the intervention, including those 
provided to participants or used in intervention delivery or in training of intervention providers. 
Provide information on where the materials can be accessed (e.g. online appendix, URL). 
N/A 
 
 
 
4. Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, 
including any enabling or support activities. 
3  
 WHO PROVIDED   
5. For each category of intervention provider (e.g. psychologist, nursing assistant), describe their 
expertise, background and any specific training given. 
3  
 HOW   
6. Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or 
telephone) of the intervention and whether it was provided individually or in a group. 
3  
 WHERE   
7. Describe the type(s) of location(s) where the intervention occurred, including any necessary 
infrastructure or relevant features. 
3  
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WHEN and HOW MUCH 
  
8. Describe the number of times the intervention was delivered and over what period of time including 
the number of sessions, their schedule, and their duration, intensity or dose. 
3  
 TAILORING   
9. If the intervention was planned to be personalised, titrated or adapted, then describe what, why, 
when, and how. 
N/A  
 MODIFICATIONS   
10.ǂ If the intervention was modified during the course of the study, describe the changes (what, why, 
when, and how). 
N/A  
 HOW WELL   
11. Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any 
strategies were used to maintain or improve fidelity, describe them. 
3  
12.ǂ 
 
Actual: If intervention adherence or fidelity was assessed, describe the extent to which the 
intervention was delivered as planned. 
Figure 1  
** Authors - use N/A if an item is not applicable for the intervention being described. Reviewers – use ‘?’ if information about the element is not reported/not   
sufficiently reported.         
† If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol      
or other published papers (provide citation details) or a website (provide the URL). 
ǂ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete. 
* We strongly recommend using this checklist in conjunction with the TIDieR guide (see BMJ 2014;348:g1687) which contains an explanation and elaboration for each item. 
* The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of 
studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a randomised trial is being reported, the 
TIDieR checklist should be used in conjunction with the CONSORT statement (see www.consort-statement.org) as an extension of Item 5 of the CONSORT 2010 Statement. 
When a clinical trial protocol is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of Item 11 of the SPIRIT 2013 
Statement (see www.spirit-statement.org). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see 
www.equator-network.org).  
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